Abstract: A recombinant multivalent vaccine including a recombinant protein is provided. The recombinant protein includes, from a N-terminus to a C-terminus, a first antigenic peptide, an N-polypeptide (SEQ ID NO: 1), a second antigenic peptide, a C-polypeptide (SEQ ID NO: 3) and a third antigenic peptide, where the N-polypeptide and the C-polypeptide are intramolecular scaffold-forming polypeptides, forming an intramolecular scaffold NC for supporting and stabilizing conformations of the first antigenic peptide, the second antigenic peptide and the third antigenic peptide. The recombinant multivalent vaccines 3Ro-NC (SEQ ID NO: 17) and 3Rs-NC (SEQ ID NO: 19) are provided to against SARS-COV-2 variants. The 3Ro-NC plus KFD is used as a prophylactic mucosal SARS-COV-2 vaccine to provide protection against Omicron infection in upper and lower respiratory tracts.

Abstract: In one embodiment, a method of building an optimized color flow cytometry panel is disclosed using a full spectrum flow cytometer with five excitation lasers and five corresponding detection modules. In another embodiment, a graphical user interface is disclosed generated by a server computer from a fluorochrome database and displayed by a client computer to assist in the selection of a set of fluorochromes for use in an assay to analyze biological samples. The GUI can display spectra graphs to visually show how fluorochromes may overlap and can generate similarity indexes for the paired fluorochrome interference and a complexity index for overall many to many interferences generated by a selected group or set of fluorochromes.

Abstract: A battery includes an electrode assembly, a first housing, and a second housing. The first housing includes a first bottom wall and a first peripheral wall. The second housing includes a second bottom wall and a second peripheral wall. The first peripheral wall is arranged outside the second peripheral wall in a sleeving manner. Here, the second peripheral wall includes a first annular segment and a second annular segment, the second annular segment is located on one side of the first annular segment back away from the second bottom wall, the first annular segment is spaced apart from the first peripheral wall with a spacing of T1, the second annular segment is spaced apart from the first peripheral wall with a spacing of T2, and 30%?T2/T1?95%.

Abstract: The present invention discloses an SMA wire-driven reusable release mechanism having a self-resetting function. The present invention adopts a structure of two-stage load reduction and one-stage release. First-stage load reduction: a compression rod and a hoop petal, as well as an inclined block and a shell or a sliding block, all cooperate with each other by means of inclined surfaces, which can transfer most of tension load of the compression rod to the shell, leaving only a small part of the load transmitted to a thrust bearing. Second-state load reduction: balls in the thrust bearing are coated with a molybdenum disulfide lubricating coating, which can effectively reduce friction so as to reduce a torque transmitted to a driving shaft. First-stage release: the driving shaft drives a thrust bearing to rotate by a certain angle, causing an upper ring of the thrust bearing to descend to release a certain axial clearance.

Abstract: The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Abstract: The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Abstract: The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Abstract: A respiratory syncytial virus (RSV) vaccine comprising a recombinant fusion protein antigen. In one embodiment, the recombinant fusion protein antigen comprises a phosphoprotein (P) moiety, wherein the P moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 2 or SEQ ID NO 4; and a flagellin moiety, wherein the flagellin moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 8; whereby the P moiety and flagellin moiety are covalently coupled so as to form a linear polypeptide.

Abstract: A respiratory syncytial virus (RSV) vaccine comprising a recombinant fusion protein antigen. In one embodiment, the recombinant fusion protein antigen comprises a phosphoprotein (P) moiety, wherein the P moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 2 or SEQ ID NO 4; and a flagellin moiety, wherein the flagellin moiety is a polypeptide that shares at least 90% identity to the polypeptide represented by SEQ ID NO 8; whereby the P moiety and flagellin moiety are covalently coupled so as to form a linear polypeptide.

Abstract: The present invention provides a vaccine composition for dental caries caused by S. mutans infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of S. mutans and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by S. mutans by administrating to a subject the vaccine composition.

Abstract: The present invention provides a vaccine composition for dental caries caused by S. mutans infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of S. mutans and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by S. mutans by administrating to a subject the vaccine composition.

Abstract: The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliC?190-278, FliC?220-320 or FliC?180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity.

Abstract: The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliC?190-278, FliC?220-320 or FliC?180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity.